1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

As Teva's Neurology Portfolio Gains Momentum, New Assets Join The Pipeline

 
• By Jessica Merrill

Q3 results show Austedo appears headed towards blockbuster status, and the company signed a collaboration with MODAG for two compounds for neurodegenerative diseases.

ripples in a pond
Teva looks to build out in neuroscience • Source: Alamy

Teva Pharmaceutical Industries Ltd.'s neurology portfolio is showing renewed growth and the company is looking to build on that foundation with the addition of two new pipeline assets, in a deal announced ahead of its third quarter sales and earnings release.

The company announced a worldwide licensing and development deal with MODAG GmbH on 26 October, gaining rights to two...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 
• By Alaric DeArment

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Sjögren’s Success For Ianalumab Shores Up Novartis’s Pipeline-In-A-Product Plans

 
• By Alexandra Shimmings

Novartis has strengthened its argument that ianalumab, its BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate, has PIP potential with successful topline results in two Phase III Sjögren’s syndrome trials, after recently dropping the product in hidradenitis suppurativa.

Genmab/AbbVie’s Epkinly Likely To See Label Expansion After Phase III Win

 
• By Alaric DeArment

The FDA is expected to rule on the anti-CD20xCD3 bispecific combined with rituximab/lenalidomide in second-line follicular lymphoma in November.